Edgewise Therapeutics (EWTX) Price & Analysis

Compare

394 Followers

EWTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.60 - $38.12

Previous CloseN/A

Volume107.81K

Average Volume (3M)603.39K

Market Cap

$1.54B

Enterprise Value$786.15M

Total Cash (Recent Filing)$593.99M

Total Debt (Recent Filing)$4.37M

Price to Earnings (P/E)―

Beta2.28

Next Earnings

Nov 06, 2025

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding105,345,710

10 Day Avg. Volume600,649

30 Day Avg. Volume603,388

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.51

Enterprise Value/Revenue371.18

Enterprise Value/Gross Profit-334.25

Enterprise Value/Ebitda-4.70

Forecast

1Y Price Target

$37.55

Price Target Upside157.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical ProgressFavorable readouts from all three clinical programs, including trials for sevasemten in BMD and DMD, and EDG-7500 in HCM, highlight promising progress in their clinical pipeline.

Financial PerformanceEdgewise announced financial results with EPS better than both the company's and consensus estimates.

Regulatory ApprovalEWTX received clear and supportive feedback towards a traditional approval for sevasemten in Becker muscular dystrophy based on a statistically significant difference on NSAA in a well-controlled study.

Bears Say

Regulatory ChallengesThe FDA did not think EWTX's CANYON data alone was sufficient to support accelerated approval but provided clear and supportive feedback towards a traditional approval.

Safety ConcernsKey debates remain on the safety front, especially focused on the elimination of left ventricular ejection fraction reduction risk, which is a key potential differentiator from existing cardiac myosin inhibitors.

Edgewise Therapeutics News

JPMorgan cuts Edgewise target, remains from Analyst Focus List

JPMorgan lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $30 from $40 and keeps an Overweight...

9d ago

EWTX

Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)

Cash, cash equivalents and marketable securities were approximately $594.0M as of June 30, 2025. “In the first half...

21d ago

EWTX

Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

29d ago

ALB

3 Best Stocks to Buy Now, 7/30/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

29d ago

HUT

BTDR

Edgewise Therapeutics initiated with a Strong Buy at Raymond James

Raymond James analyst Martin Auster initiated coverage of Edgewise Therapeutics (EWTX) with a Strong Buy rating and $46...

30d ago

EWTX

Edgewise Therapeutics Advances in Muscular Dystrophy Trials

Edgewise Therapeutics, Inc. ( ($EWTX) ) has released its Q2 earnings. Here is a breakdown of the information...

20d ago

EWTX

Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating

Edgewise Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

21d ago

EWTX

Edgewise Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Edgewise Therapeutics (EWTX) with a Buy rating and $42 price target The clinical-stage...

2M ago

EWTX

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and...

2M ago

EWTX

Edgewise Therapeutics Announces Positive Sevasemten Results

Edgewise Therapeutics ( ($EWTX) ) has provided an announcement. On June 26, 2025, Edgewise Therapeutics announced positive results...

2M ago

EWTX

Morning Movers: Shell ticks higher after denying interest in BP deal

Stock futures are drifting cautiously higher as the S&P edges close to record highs. The dollar is under...

2M ago

Edgewise update in line with expectations, says Leerink

Edgewise Therapeutics (EWTX) announced that while the FDA deemed the CANYON data insufficient to support accelerated approval on...

2M ago

EWTX

Truist sees ‘slight weakness’ for Edgewise Therapeutics on regulatory feedback

Truist keeps a Buy rating with a $50 price target on Edgewise Therapeutics (EWTX) after the company’s updates...

2M ago

EWTX

Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges

Edgewise Therapeutics (EWTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

EWTX

EWTX FAQ

What was Edgewise Therapeutics’s price range in the past 12 months?

Edgewise Therapeutics lowest stock price was $10.60 and its highest was $38.12 in the past 12 months.

What is Edgewise Therapeutics’s market cap?

Edgewise Therapeutics’s market cap is $1.54B.

When is Edgewise Therapeutics’s upcoming earnings report date?

Edgewise Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 70 days.

How were Edgewise Therapeutics’s earnings last quarter?

Edgewise Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.074.

Is Edgewise Therapeutics overvalued?

According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Edgewise Therapeutics pay dividends?

Edgewise Therapeutics does not currently pay dividends.

What is Edgewise Therapeutics’s EPS estimate?

Edgewise Therapeutics’s EPS estimate is -0.4.

How many shares outstanding does Edgewise Therapeutics have?

Edgewise Therapeutics has 105,345,710 shares outstanding.

What happened to Edgewise Therapeutics’s price movement after its last earnings report?

Edgewise Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went down -4.216%.

Which hedge fund is a major shareholder of Edgewise Therapeutics?

Currently, no hedge funds are holding shares in EWTX

Edgewise Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-27.41%

Trailing 12-Months

Asset Growth

15.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics (EWTX) Earnings & Revenues

Historic Earnings Reports

EWTX Stock 12 Month Forecast

Average Price Target

$37.55

▲(157.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","52":"$52","21.25":"$21.3","31.5":"$31.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21.25,31.5,41.75,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.31,17.13230769230769,19.954615384615384,22.776923076923076,25.59923076923077,28.42153846153846,31.24384615384615,34.066153846153846,36.888461538461534,39.71076923076923,42.53307692307692,45.355384615384615,48.177692307692304,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.31,16.09769230769231,17.885384615384616,19.673076923076923,21.46076923076923,23.248461538461537,25.036153846153844,26.82384615384615,28.61153846153846,30.39923076923077,32.18692307692307,33.97461538461538,35.76230769230769,{"y":37.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.31,14.286153846153846,14.262307692307692,14.23846153846154,14.214615384615385,14.19076923076923,14.166923076923077,14.143076923076924,14.11923076923077,14.095384615384615,14.071538461538461,14.047692307692309,14.023846153846154,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >